Safety and Efficacy Results From ABOUND.70+: nab-Paclitaxel/Carboplatin in Elderly Patients With Advanced NSCLC

被引：0

作者：

Langer, Corey ^{[1
]}

Goldman, Jonathan ^{[2
]}

Amiri, Kathy ^{[3
]}

Anderson, Eric ^{[4
]}

DakhiLs, Shaker ^{[5
]}

Haggstrom, Daniel ^{[6
]}

Jotte, Robert ^{[7
]}

Konduri, Kartik ^{[8
]}

Modiano, Manuel ^{[9
]}

Ong, Teng ^{[3
]}

Sanford, Alexandra ^{[3
]}

Smith, David ^{[10
]}

Socoteanu, Matei ^{[11
]}

Kim, Edward ^{[6
]}

Weiss, Jared ^{[12
]}

机构：

[1] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[2] Univ Calif Los Angeles, Los Angeles, CA USA

[3] Celgene Corp, Summit, NJ USA

[4] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA

[5] Canc Ctr Kansas, Wichita, KS USA

[6] Carolinas Healthcare Syst, Levine Canc Inst, Charlotte, NC USA

[7] Rocky Mt Canc Ctr, Denver, CO USA

[8] Baylor Charles A Sammons Canc Ctr, Texas Oncol Pa, Dallas, TX USA

[9] Acrc, Tucson, AZ USA

[10] Compass Oncol, Vancouver, WA USA

[11] Longview, Texas Oncol, Tyler, TX USA

[12] Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA

来源：

关键词：

Safety; efficacy; elderly; nab-paclitaxel;

D O I：

10.1016/j.jtho.2016.11.1256

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P2.03a-046

引用

页码：S916 / S917

页数：2